Tubastatin A structure
|
Common Name | Tubastatin A | ||
---|---|---|---|---|
CAS Number | 1239262-52-2 | Molecular Weight | 449.42 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | N/A | |
Molecular Formula | C22H22F3N3O4 | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | N/A |
Use of Tubastatin ATubastatin A (TSA) TFA is a potent and selective?HDAC6?inhibitor with?IC50?of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A TFA also inhibits HDAC10 and metallo-β-lactamase domain-containing protein?2 (MBLAC2). |
Name | Tubastatin A Trifluoroacetate |
---|---|
Synonym | More Synonyms |
Description | Tubastatin A (TSA) TFA is a potent and selective?HDAC6?inhibitor with?IC50?of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A TFA also inhibits HDAC10 and metallo-β-lactamase domain-containing protein?2 (MBLAC2). |
---|---|
Related Catalog | |
Target |
IC50: 15 nM (HDAC6)[1] |
In Vitro | Tubastatin A is substantially selective for all 11 HDAC isoforms and maintains over 1000-fold selectivity against all isoforms excluding HDAC8, where it has approximately 57-fold selectivity. In homocysteic acid (HCA) induced neurodegeneration assays, Tubastatin A displays dose-dependent protection against HCA-induced neuronal cell death starting at 5 μM with near complete protection at 10 μM[1].?At 100 ng/mL Tubastatin A increases Foxp3+ T-regulatory cells (Tregs) suppression of T cell proliferation in vitro[2].?Tubastatin A treatment in CC12 cells would lead to myotube formation impairment when alpha-tubulin is hyperacetylated early in the myogenic process; however, myotube elongation occurs when alpha-tubulin is hyeperacetylated in myotubes[3].?A recent study indicates that Tubastatin A treatment increases cell elasticity as revealed by atomic force microscopy (AFM) tests without exerting drastic changes to the actin microfilament or microtubule networks in mouse ovarian cancer cell lines, MOSE-E and MOSE-L[4]. |
In Vivo | Daily treatment of Tubastatin A at 0.5 mg/kg inhibits HDAC6 to promote Tregs suppressive activity in mouse models of inflammation and autoimmunity, including multiple forms of experimental colitis and fully major histocompatibility complex (MHC)-incompatible cardiac allograft rejection[2]. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Molecular Formula | C22H22F3N3O4 |
Molecular Weight | 449.42 |
Exact Mass | 335.163391 |
PSA | 94.80000 |
LogP | 2.14 |
Index of Refraction | 1.668 |
~31% Tubastatin A CAS#:1239262-52-2 |
Literature: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS; KOZIKOWSKI, Alan; BUTLER, Kyle, B.; KALIN, Jay, Hans Patent: WO2011/11186 A2, 2011 ; Location in patent: Page/Page column 54-55 ; WO 2011/011186 A2 |
~% Tubastatin A CAS#:1239262-52-2 |
Literature: WO2011/11186 A2, ; WO 2011/011186 A2 |
~% Tubastatin A CAS#:1239262-52-2 |
Literature: WO2011/11186 A2, ; WO 2011/011186 A2 |
~% Tubastatin A CAS#:1239262-52-2 |
Literature: WO2011/11186 A2, ; WO 2011/011186 A2 |
~% Tubastatin A CAS#:1239262-52-2 |
Literature: Journal of the American Chemical Society, , vol. 132, # 31 p. 10842 - 10846 |
TUBASTATIN A HYDROCHLORIDE |
N-hydroxy-4-({2-methyl-1H,3H,4H-pyrido[4,3-b]indol-5-yl}methyl)benzamide hydrochloride |
N-Hydroxy-4-[(2-methyl-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-5-yl)methyl]benzamide |
Benzamide, N-hydroxy-4-[(1,2,3,4-tetrahydro-2-methyl-5H-pyrido[4,3-b]indol-5-yl)methyl]- |
Tubastatin A Trifluoroacetic Acid Salt |
TUBASTSTINA HCL |
TUBASTATIN A ((2-METHYL-3,4-DIHYDRO-1H-PYRIDO[4,3-B]-INDOL- 5(2H)-YL)METHYL)BENZAMIDE) |
TUBASTATIN A_HCL |
Tubastatin A |
TUBASTANTIN A |
Tubastatin A (trifluoroacetate salt) |
TRIETHYLENETHIOPHOSPHORAMIDE,WHITE SOLID |
[4-({2-methyl-1H,2H,3H,4H,5H-pyrido[4,3-b]indol-5-yl}methyl)phenyl]formamido 2,2,2-trifluoroacetate |
N-Hydroxy-4-[(2-methyl-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-5 -yl)methyl]benzamide |
N-hydroxy-4-((2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)methyl)benzamide |